The North West Coast Genomic Medicine Centre (NWC GMC) has been set up to help gain a better understanding of the genetic causes of cancer and rare diseases.
It is part of the 100,000 Genomes Project, which aims to sequence, or analyse, 100,000 genomes from participants with cancer, rare disorders and infectious disease.
100,000 Genomes Project: Consent Evaluation
By studying the function and the structure of the human genome (genomics) scientists can begin to establish the precise causes of disease. Comment acheter kamagra en France
The NWC GMC represents a number of NHS organisations working together, led by Liverpool Women’s Hospital NHS Foundation Trust and supported by the Royal Liverpool and Broadgreen University Hospitals NHS Trust; The Walton Centre NHS Foundation Trust; Liverpool Heart and Chest Hospital NHS Foundation Trust; Alder Hey Children’s Hospital NHS Foundation Trust, the Countess of Chester NHS Foundation Trust, Lancashire Teaching NHS Foundation Trust, the North West Coast Academic Health Science Network and Liverpool Health Partners.
The Centre forms part of a world-leading programme in the use of genomics and genetic technologies for participant benefit within the NHS. It will also be a major driver in ensuring that genomic medicine becomes main stream in the NHS associated with the move towards predicting and preventing disease, and more precisely diagnosing disease and personalising treatment.
The partnership will aim to recruit up to 8,000 patients who have been given a new diagnosis of diseases such as breast, lung or ovarian cancer, cancer du sein. The initiative will then work to uncover patterns about specific genetic conditions.
There are between 6,000 and 8,000 known rare diseases worldwide. Each disease or syndrome may affect less than 0.1% of the UK’s population, but cumulatively they affect the lives of 3 million people, and are associated with significant morbidity and mortality.
The NWC GMC is responsible for recruiting and obtaining a sample of blood for the extraction of host DNA, as well as providing the participant’s clinical data.